Extedo adds two to management board
Directors will be based in Germany and US respectively
Schmid joins the organisation as president and now shares day-to-day operational responsibilities with chief executive Tore Bergsteiner.
Dude has taken the position of managing director at Extedo Inc in the US, to support the organisation’s expansion in North America.
Schmid will head up the global marketing and sales organisation as well as the Product Management Unit, which are key areas for Extedo. He will be based in Ottobrunn, Germany.
Schmid has more than 15 years of experience in management consulting, marketing and sales.
Dude will be based in West Chester, PA. He has more than 20 years of experience in the IT services and software industries with Prime Technology Group, Glemser Technologies, First Consulting Group and Thomson Financial.
You may also like
Regulatory
FDA rejects Summit Therapeutics’ ivonescimab lung cancer drug
The US regulator has issued a complete response letter for the PD-1/VEGF bispecific antibody, citing a lack of statistically significant overall survival benefit in a Phase III trial despite improvements in progression-free survival
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
Right-sized, not oversized: rethinking quality management technology for the UK's growing manufacturers (part II)
How the enterprise trap is set: familiar platforms, borrowed requirements and hidden validation costs can turn seemingly safe purchasing decisions into costly operational burdens
Regulatory
EU combination products: MDR, article 117 and drug-device approval risks
Bringing a drug-device combination product to market in Europe requires more than a strong pharmaceutical dossier and a functional delivery device. Companies must align two different development models, satisfy EU MDR expectations, manage notified-body involvement, and demonstrate that the drug and device work safely as one integrated product
Regulatory
Is your combination product really submission-ready?
A pharmaceutical team may consider a combination product nearly ready because the clinical, stability, quality, and drug data are in place. At the same time, the device team may still be completing design verification, usability studies, risk-management activities, or notified-body preparation
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.